688068 Beijing Hotgen Biotech Co.,Ltd
WatchlistBeijing Hotgen Biotech Co.,Ltd News
Hot Scene Biology (688068.SH): Currently, there is no brain-computer interface layout
On November 30, Gelonghui (688068.SH) said on an interactive platform that the company, as the first IVD company listed on the Science and Technology Innovation Board, has always used scientific and technological innovation as the company's development concept, strengthened the main in vitro diagnostic business, and expanded new fields and strategic layout based on biotechnology trends. Currently, there is no brain-computer interface.
Hot Scene Biology (688068.SH): Projects related to Alzheimer's disease test reagents are in the R&D and registration stages
On November 30, Gelonghui (688068.SH) said on an interactive platform that projects related to Alzheimer's disease (AD) testing reagents are in the R&D and registration stages. Please continue to pay attention to the company's follow-up announcements for specific progress.
Hot View Biotech: Revenue plummeted, routine clinical business increased 40% | Direct impact on performance
① Lin Changqing, chairman of Hot View Biotech, said that in the first three quarters of 2023, the growth rate of routine clinical business will be around 40%; ② “Entering the field of innovative biotechnology also takes biotechnology as the main line, and has good collaborative development benefits with the company's existing main business.”
Hot Scene Biology (688068.SH): Currently, collection in Anhui mainly involves HPV, pre-operative eight items, hormones, diabetes, etc., and has little impact on the company
On November 10, Gelonghui (688068.SH) said in an investor survey that the current collection in Anhui mainly involves HPV, pre-operative eight items, hormones, diabetes, etc., and has little impact on the company. It is not ruled out whether the scope will continue to expand in the later stages. The company also continues to pay attention to the latest policies. At the same time, the company has a large variety of innovations, so the impact on revenue will not be significant.
Changes in A-shares | Hot Spot Biotech rose more than 12% and has deployed test reagents for Alzheimer's disease
Gelonghui November 8 | Hot Spot Biotech (688068.SH) rose more than 12% to 48.37 yuan, a five-month high, with a total market value of 4.463 billion yuan. In response to questions from investors on an interactive platform on November 7, Hot View Biotech said that in terms of testing reagents for Alzheimer's disease (AD), the company and the participating company Zhiyuan Pharmaceutical have a layout. Among them, the company's testing indicators for AD testing are mainly Tau protein series test kits, a total of 4 types; Zhiyuan Pharmaceutical also has products for AD testing.
Hot View Biotech (688068.SH) and its subsidiaries obtained 3 domestic Class II medical device registration certificates and 3 overseas qualification certifications in July-October
Hot View Biotech (688068.SH) announced that the company and subsidiaries won the domestic Class II category from July to October 2023...
Hot View Biotech (688068.SH): Net profit for the first three quarters was 54.381 million yuan, a year-on-year decrease of 95.06%
On October 30, Gelonghui (688068.SH) released its report for the first three quarters of 2023. The reporting period achieved operating income of 407 million yuan, a year-on-year decrease of 86.48%; net profit attributable to shareholders of listed companies was 54.381 million yuan, a year-on-year decrease of 95.06%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 109.398 million yuan, a year-on-year decrease of 98.99%; basic earnings per share of 0.61 yuan.
Hot Scenery Biology (688068.SH): An innovative small nucleic acid drug for fat loss, sugar reduction, and weight loss, also has a related layout
Glonghui, Oct. 24, 丨 Hot View Biotech (688068.SH) said at an investor relations event that the company's subsidiary, Beijing Yaojing Gene Technology Co., Ltd. is a high-tech biotechnology enterprise focusing on the development and application of innovative drugs in the field of anti-aging. Focusing on metabolic diseases related to aging, it has established multiple core technology platforms such as a new target discovery platform, a high-throughput efficacy evaluation platform, a bioinformation and artificial intelligence development platform, and has laid out a series of innovative nucleic acid drug pipelines. Among them, innovative small nucleic acid drugs for fat loss, sugar reduction, and weight loss also have a relevant layout.
Hot Scenery Biology (688068.SH): It has completed research and development of many respiratory related test reagents, including Mycoplasma pneumoniae, and is in the process of registration
Glonghui, Oct. 24 | Hot Scenery Biotech (688068.SH) said at an investor relations event that the company's C900 and MQ60 single-dose chemiluminescence technology platforms can develop rapid detection reagents for different objects to be tested, and can also guide medical staff. We have completed research and development of many respiratory related test reagents, including Mycoplasma pneumoniae, and are in the process of registering them.
Should Weakness in Beijing Hotgen Biotech Co., Ltd.'s (SHSE:688068) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Beijing Hotgen Biotech (SHSE:688068) has had a rough week with its share price down 17%. However, stock prices are usually driven by a company's financials over the long term, which in this case loo
Shareholder of Hot Spring Biotech (688068.SH), Tongcheng Hot Jing, reduced the company's holdings by a total of 922,600 shares
Hot Scenery Biology (688068.SH) announced that as of October 9, the current holdings reduction plan has expired, and shareholders agree...
Hot Scenery Biology (688068.SH): Plans to raise 3,0663,600 yuan in savings to permanently supplement working capital
Glonghui, September 13, 丨 Hot Scenery Biotech (688068.SH) announced that since the company's fund-raising investment project “12 million in vitro diagnostic reagents, 850 supporting instruments production base and R&D center project” has been completed and put into use, in line with actual business conditions, in order to improve the efficiency of the use of capital raised, the company plans to raise funds saved from this fund-raising investment project of 3,0063,600 yuan (including interest income. The actual transfer amount is based on the bank account balance on the day the funds were transferred out) to permanently supplement the working capital for the company's daily production and operation.
Hot Scenery Bio (688068.SH) released first-half results, net profit of 84.7687 million yuan, a year-on-year decrease of 89.60%
Hot Scenery Biology (688068.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
The main shareholder of Hot Jing Biotech (688068.SH) reduced their holdings by a total of 922,600 shares
According to the Zhitong Finance App, Hotjing Biotech (688068.SH) announced that Qingdao Tongcheng Hot Jing Enterprise Management Consulting Partnership (Limited Partnership) (“Tongcheng Hot Jing”), which holds more than 5% of the company's shares, has reduced its holdings by 922,600 shares, accounting for 1.00% of the total share capital. The number of holdings reduced in this holdings reduction plan is more than half.
Hot Scene Biology (688068.SH) obtained 15 qualifications in April-6
According to the Zhitong Finance App, Hot View Biology (688068.SH) announced that the company and its subsidiaries obtained 4 domestic Class II medical device registration certificates from April to June 2023, for a total of 11 overseas qualification certifications. The acquisition of the above qualifications has enriched the variety of the company's products and will enhance the company's overall competitiveness. It is conducive to further improving the company's intellectual property protection system, further improving the company's market expansion capabilities, and enhancing the company's core competitiveness. As of the disclosure date of the announcement, all of the above products had obtained relevant production licenses, which had little impact on the company's business performance in the short term.
Hot View Biotech (688068.SH): Obtained 4 domestic Class II medical device registration certificates in the second quarter, and obtained a total of 11 overseas qualification certifications
On July 26, GLONGHUI | Hot View Biotech (688068.SH) announced that the company and its subsidiaries obtained 4 domestic Class II medical device registration certificates from April to June 2023, for a total of 11 overseas qualification certifications.
Hot View Biotech (688068.SH): Plans to increase the capital of participating companies by a total of 40 million yuan
On July 18, GLONGHUI | Hot View Biotech (688068.SH) announced that Zhiyuan Biotech is a shareholding company with 20% of the company's shares, and its main business is research and development of innovative biological drugs and diagnostic reagents. In order to further optimize the company's business layout and expand the company's development strategy in the field of bioinnovative pharmaceuticals, the company plans to jointly invest 40 million yuan in strategic investment enterprise Shunjing Pharmaceutical to increase its capital. Of these, the company will increase its capital with its own capital of 35 million yuan, of which 425,800 yuan has been subscribed to additional registered capital, and the portion of the investment amount exceeding the subscribed registered capital of 32.57542 million yuan will be included in Zhiyuan Seng
Hot View Biotech received a supervisory work letter from the Shanghai Stock Exchange
Glonhui, July 11丨Hot View Biotech received a supervisory work letter from the Shanghai Stock Exchange, involving listed companies, directors, intermediaries and their related personnel. Subject of processing: Regulatory working letter on Beijing Rejing Biotechnology Co., Ltd.
Zhou Zinc, the main shareholder of Hot Jing Biotech (688068.SH), did not reduce his holdings for more than half of the Tongcheng Rejing holdings reduction period
According to the Zhitong Finance App, Hot Jing Biotech (688068.SH) announced that Zhou Zinc, a shareholder holding more than 5% of the company's shares, and Qingdao Tongcheng Hot Jing Enterprise Management Consulting Partnership (Limited Partnership) (“Tongcheng Hot Jing”) have not reduced their holdings of the company's shares. The current holdings reduction plan has already cut their holdings by more than half.
Hot Jing Biotech (688068.SH) plans to invest 200 million yuan in funds related to the healthcare sector to create Jing Kangrun
According to the Zhitong Finance App, Hot View Biotech (688068.SH) announced that based on long-term strategic goal planning, combined with the existing investment management experience of the founding team of Qingdao Chuangjing Private Equity Fund Management Co., Ltd. (hereinafter referred to as “Chuangjing Capital”) and other limited partner-related industry resource advantages, the company explores and discovers new business growth points to further explore development opportunities in healthcare segments such as in vitro diagnosis (IVD), innovative drugs, medical devices, life sciences, etc. Proposed use of own capital and creativity